Pro-EU parties are set to hold onto two-thirds of the seats at the EU Parliament.Europe Politicsread more
The projected result comes shortly after Conservative Party leader Theresa May announced her resignation as prime minister on Friday morning.Europe Politicsread more
Stocks in Asia were were mixed in Monday morning trade as investors watched for developments from U.S. President Donald Trump's state visit to Japan as well as results from...Asia Marketsread more
Sources say the talks, which have been happening over the last several weeks, have picked up speed in recent days and could lead to an announcement regarding a merger or...Autosread more
Biden had criticized Kim Jong Un as a "dictator" and a "tyrant" at a recent rally in Philadelphia. North Korean state media responded by calling Biden a "fool of low IQ" among...Politicsread more
Book income helped self-proclaimed socialist Bernie Sanders join the millionaire class, a group he has often criticized during his decades in politics.Politicsread more
Exit polls showed National Rally, a re-branding of Le Pen's National Front, beating Macron's party by just one seat.Europe Politicsread more
Stocks that are most prone to swine flu fears include Bloomin' Brands, Phibro, Darling Ingredients, Deere, and Hormel, according to analysts.Marketsread more
Trump was speaking at a meeting of Japanese business leaders in Tokyo during his state visit to Japan on Saturday.Marketsread more
You should use your summer vacation to unwind from work stress. Here are some tips for disconnecting while you're away.Technologyread more
If you value reliability and quality over a posh cabin and jealous looks, the Lexus LX 570 two-row is the Japanese Range Rover you need.Autosread more
Spending on prescription medicines in the United States will increase 4 percent to 7 percent through 2021, reaching $580 billion to $610 billion, according to a report released by QuintilesIMS Holding on Thursday that lowered its prior long-term forecast.
QuintilesIMS, which compiles data for the pharmaceutical industry, had previously forecast average spending growth of 6 percent to 9 percent through 2021. It reduced its projections due to fewer new medicines approved in 2016 than prior years and as drugmakers face increasing pricing pressure and competition.
Taking likely manufacturer discounts and rebates into account, spending would grow 2 percent to 5 percent to $375 billion to $405 billion in 2021, as net price increases for patent-protected branded drugs slows, the report said.
Under pressure from politicians and insurers over the cost of many branded medicines, several drugmakers have pledged to limit annual price hikes to under 10 percent.
"We're forecasting moderation in pricing reflecting what ... we expect will be a continuing trend of single-digit price increases," said Murray Aitken, executive director of the QuintilesIMS Institute which compiled the report.
Some of the expense of new medicines will be offset by expanded use of cheap generics as several big-selling prescription drugs lose patent exclusivity and more biosimilars - less expensive versions of pricey biotech medicines - enter the market.
The U.S. Food and Drug Administration approved just 22 new medicines last year, down from 45 in 2015, which will also contribute to lower spending growth this year and next, the report said.
That is seen picking up in 2019 and beyond as QuintilesIMS estimates 40 to 45 new brand launches per year through 2021 based on a review of experimental medicines in drugmaker pipelines.
The report found more than 2,300 novel products in later stage development, including more than 600 drugs for cancer, which remain able to command very high prices.
"Numbers (of approvals) are already running well ahead of where they were a year ago," Aitken said.
U.S. spending on prescription medicines in 2016 increased by 5.8 percent over 2015 levels to $450 billion based on list prices, and by 4.8 percent to $323 billion when adjusted for discounts and rebates.
The biggest drivers of prescription growth came from large chronic therapy areas, such as hypertension and mental health.
Overall use of pain medicines declined 1 percent with restrictions on prescribing and dispensing becoming more common as healthcare providers attempt to address the growing epidemic of addiction to opioid pain drugs.